Table 1. Stratified analysis of XRCC1 Arg399Gln polymorphism on cancer risk1.
| Variables | No. comparisons(SZ case/control) | Dominant model | Recessive model | Additive model | |||
| OR (95% CI) | P h /I 2 | OR (95% CI) | P h /I 2 | OR (95% CI) | P h /I 2 | ||
| Overall | 297 (93,941/121,480) | 1.04 (1.01–1.07)* | <0.001/52.6% | 1.08 (1.03–1.13)* | <0.001/48.8% | 1.09 (1.04–1.14)* | <0.001/49.4% |
| Cancer type | |||||||
| Bladder cancer | 20 (6,376/7,393) | 1.02 (0.95–1.09) | 0.256/15.9% | 0.87 (0.78–0.97) | 0.430/2.1% | 0.90 (0.80–1.01) | 0.335/10.2% |
| Breast cancer | 54 (29,549/32,619) | 1.05 (0.99–1.10)* | <0.001/46.8% | 1.09 (1.00–1.18)* | <0.001/50.6% | 1.10 (1.01–1.20)* | <0.001/49.1% |
| Cervical cancer | 6 (1,025/1,690) | 1.00 (0.71–1.41)* | 0.005/70.3% | 1.37 (1.03–1.81) | 0.765/0.0% | 1.37 (1.02–1.84) | 0.134/43.1% |
| Colorectal cancer | 27 (7,919/12,385) | 1.07 (0.96–1.18)* | 0.001/53.6% | 1.18 (1.00–1.39)* | 0.001/54.2% | 1.18 (1.00–1.42)* | <0.001/57.4% |
| Esophageal cancer | 14 (3,166/6,244) | 0.99 (0.88–1.12)* | 0.050/41.9% | 1.13 (0.93–1.37)* | 0.061/40.0% | 1.13 (0.90–1.41)* | 0.019/49.4% |
| Gastric cancer | 15 (3,382/7,282) | 1.00 (0.86–1.15)* | 0.002/59.1% | 1.08 (0.94–1.25) | 0.479/0.0% | 1.07 (0.93–1.25) | 0.155/27.3% |
| Glioma | 7 (2,487/3,629) | 2 | <0.001/87.8% | 2 | <0.001/79.9% | 2 | <0.001/88.1% |
| Hepatocellularcancer | 9 (1,621/2,310) | 1.18 (0.92–1.50)* | 0.009/60.5% | 1.13 (0.90–1.42) | 0.978/0.0% | 1.23 (0.96–1.59) | 0.829/0.0% |
| Head and neckcancer | 39 (8,535/12,255) | 0.99 (0.91–1.08)* | <0.001/52.2% | 0.97 (0.86–1.09)* | 0.035/31.3% | 0.97 (0.84–1.11)* | 0.004/41.5% |
| Leukemia | 15 (2,261/2,854) | 1.24 (1.00–1.53)* | <0.001/66.8% | 1.09 (0.91–1.30) | 0.206/22.8% | 1.23 (0.91–1.67)* | 0.009/53.5% |
| Lung cancer | 41 (14,156/16,667) | 1.00 (0.94–1.07)* | 0.009/37.9% | 1.05 (0.94–1.18)* | 0.017/36.4% | 1.05 (0.93–1.19)* | 0.003/43.3% |
| Lymphoma | 4 (827/1,414) | 1.10 (0.92–1.32) | 0.802/0.0% | 1.15 (0.86–1.54) | 0.759/0.0% | 1.20 (0.88–1.64) | 0.773/0.0% |
| Pancreatic cancer | 6 (1,247/2,222) | 0.99 (0.86–1.15) | 0.293/18.5% | 1.04 (0.83–1.29) | 0.783/0.0% | 1.03 (0.82–1.30) | 0.510/0.0% |
| Prostate cancer | 18 (4,452/4,431) | 1.05 (0.89–1.23)* | <0.001/63.0% | 1.20 (0.99–1.45)* | 0.028/43.7% | 1.18 (0.97–1.43)* | 0.093/32.9% |
| Skin cancer | 13 (4,763/5,471) | 0.99 (0.91–1.07) | 0.476/0.0% | 0.95 (0.84–1.07) | 0.170/27.2% | 0.95 (0.84–1.08) | 0.305/13.9% |
| Other cancer | 9 (2,175/2,614) | 2 | <0.001/78.7% | 2 | <0.001/89.7% | 2 | <0.001/84.4% |
1
all summary ORs were calculated using fixed-effects models. In the case of significant heterogeneity (indicated by *), ORs were calculated using random-effects models;
2
the results were excluded due to high heterogeneity; the bold values indicate that the results are statistically significant.